NanoString® Technologies develops innovative products that unlock valuable and clinically actionable genomic information from small amounts of tissue. We are committed to providing tools that enable scientists and clinicians to translate today’s leading research into clinically actionable tests that improve patient care.

The nCounter® Analysis System and related consumables have been adopted by academic, government and commercial research laboratories worldwide. The Prosigna™ Breast Cancer Assay, which received European Union regulatory clearance in September 2012, and launched in February 2013, represents our initial offering in the molecular diagnostics market.

nCounter® Analysis System

The nCounter® Analysis System is an automated, multi-application, digital detection and counting system which directly profiles up to 800 molecules simultaneously from a single sample using a novel barcoding technology. The system has the performance required for today’s most demanding research applications, yet is simple enough for use in clinical laboratories worldwide.

NanoString’s Prosigna™ breast cancer prognostic gene signature assay recently received the CE Mark, allowing NanoString to offer this test on its nCounter® Analysis System in the European Union.
Presently, in the U.S., the nCounter Analysis System is available for research use only.

Pathway-based Translational Research

The nCounter® Analysis System is optimized for pathway-based biological research, enabling researchers to analyze interactions among hundreds of genes that mediate biological pathways. Our system is particularly useful for validating complex networks of genes that characterize and help predict disease states, enabling the development of diagnostics and medicines designed specifically for treating patients with certain genomic profiles.

Oncology

Cancer research is typically conducted using biopsies that are stored in a format known as Formalin-Fixed Paraffin-Embedded, or FFPE, which complicates subsequent analysis of genetic material. Our robust amplification-free chemistry allows researchers to measure subtle changes in genomic activity in very small FFPE samples, with little or no performance degradation when compared to analysis of fresh/frozen tissue. This key benefit has made the nCounter® Analysis System the analysis method of choice for cancer researchers worldwide.

Molecular Dx

Advances in genomic research are driving a revolution in personalized medicine that is accelerating innovation in patient care. Genomic-based diagnostic tests have demonstrated the ability to identify the hallmark genetic changes that drive many diseases, including cancer. By leveraging the precision, reproducibility, and mobility of NanoString’s nCounter Analysis System we are empowering local centers to achieve a level of diagnostic clarity only previously available through a central lab. We believe our new approach to complex genomic analysis will transform the current paradigm by making comprehensive personalized diagnosis accessible to patients worldwide.